XML 79 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Narrative) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Effective income tax rate 56.00% 4.00% 41.00%
FDII deduction $ 1,100,000    
Interest deductibility threshold 30.00%    
Interest deduction limit $ 4,900,000    
Excess interest not deducted 21,100,000    
Other 169,000 $ 18,000 $ 88,000
Reversal in uncertain tax positions (154,000) (67,000) (153,000)
Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations $ 467,000 $ 254,000 $ 227,000
Federal statutory income tax rate 21.00% 34.00% 35.00%
Valuation allowances against deferred tax assets $ 3,372,000 $ 2,469,000  
Net deferred tax liability 23,156,000 28,821,000  
Federal net operating loss carryforwards related to the acquisitions of Cardiogenesis and Hemosphere 3,100,000    
State net operating loss carryforwards 3,000,000    
Foreign net operating loss carryforwards 2,300,000    
Research and development tax credit carryforwards 648,000    
Total uncertain tax liability including interest and penalties 4,300,000 4,600,000  
Uncertain tax liability recorded as reduction to deferred tax assets 286,000 146,000  
Uncertain tax liability recorded to non-current liability 4,000,000 $ 4,500,000  
Approximate amount of uncertain tax liability to be recognized in 2018 1,200,000    
Expires Tax Year 2025 [Member]      
Foreign net operating loss carryforwards $ 832,000    
Research [Member]      
Tax credit carryforwards expiration date Dec. 31, 2022    
Texas Tax Credit [Member]      
Other tax credit $ 164,000    
Federal [Member]      
Operating loss carryforwards expiration date Dec. 31, 2018    
State [Member]      
Operating loss carryforwards expiration date Dec. 31, 2022    
Foreign Authority [Member]      
Operating loss carryforwards expiration date Dec. 31, 2025    
Texas [Member] | State [Member]      
Tax credit carryforwards expiration date Dec. 31, 2027